Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics

References

• Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement. 2016;12(4):459–509.
   Google Scholar
• McGeer PL, McGeer E, Rogers J, et al. Anti-inflammatory drugs and Alzheimer disease. Lancet. 1990;335:1037.
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–185.
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12(9):1005–1015.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.
   PubMed Web of Science ®Google Scholar
• Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell. 2013;153(3):707–720.
   PubMed Web of Science ®Google Scholar
• Weitz TM, Town T. Microglia in Alzheimer’s disease: it’s all about context. Int J Alzheimers Dis. 2012;2012:314185.
   PubMedGoogle Scholar
• Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20.
   PubMed Web of Science ®Google Scholar
• Mandrekar S, Jiang Q, Lee CY, et al. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci. 2009;29(13):4252–4262.
   PubMed Web of Science ®Google Scholar
• Guillot-Sestier MV, Town T. Innate immunity in Alzheimer’s disease: a complex affair. CNS Neurol Disord Drug Targets. 2013;12(5):593–607.
   PubMed Web of Science ®Google Scholar
• Floden AM, Combs CK. Microglia demonstrate age-dependent interaction with amyloid-beta fibrils. J Alzheimers Dis. 2011;25(2):279–293.
   PubMed Web of Science ®Google Scholar
• Bhaskar K, Maphis N, Xu G, et al. Microglial derived tumor necrosis factor-alpha drives Alzheimer’s disease-related neuronal cell cycle events. Neurobiol Dis. 2014;62:273–285.
   PubMed Web of Science ®Google Scholar
• Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677–687.
   PubMed Web of Science ®Google Scholar
• Thal DR. The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp Neurol. 2012;236(1):1–5.
   PubMed Web of Science ®Google Scholar
• Bhat R, Crowe EP, Bitto A, et al. Astrocyte senescence as a component of Alzheimer’s disease. PLoS One. 2012;7(9):e45069.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology. 1996;47(2):425–432.
   PubMed Web of Science ®Google Scholar
• Hoozemans JJ, Rozemuller JM, Van Haastert ES, et al. Cyclooxygenase-1 and −2 in the different stages of Alzheimer’s disease pathology. Curr Pharm Des. 2008;14(14):1419–1427.
   PubMed Web of Science ®Google Scholar
• Yasojima K, Schwab C, McGeer EG, et al. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 1999;830(2):226–236.
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28(5):639–647.
   PubMed Web of Science ®Google Scholar
• Choi SH, Bosetti F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY). 2009;1(2):234–244.
   PubMedGoogle Scholar
• Kotilinek LA, Westerman MA, Wang Q, et al. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain. 2008;131(Pt 3):651–664.
   PubMed Web of Science ®Google Scholar
• Woodling NS, Andreasson KI. Untangling the web: toxic and protective effects of neuroinflammation and PGE2 signaling in Alzheimer’s disease. ACS Chem Neurosci. 2016;7(4):454–463.
   PubMed Web of Science ®Google Scholar
• Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage. Curr Top Med Chem. 2008;8(1):47–53.
   PubMed Web of Science ®Google Scholar
• Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112(3):440–449.
   PubMed Web of Science ®Google Scholar
• Hirohata M, Ono K, Naiki H, et al. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. Neuropharmacology. 2005;49(7):1088–1099.
   PubMed Web of Science ®Google Scholar
• Avramovich Y, Amit T, Youdim MB. Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J Biol Chem. 2002;277(35):31466–31473.
   PubMed Web of Science ®Google Scholar
• Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82–86.
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272(6):3406–3410.
   PubMed Web of Science ®Google Scholar
• Sastre M, Dewachter I, Landreth GE, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci. 2003;23(30):9796–9804.
   PubMed Web of Science ®Google Scholar
• Sastre M, Dewachter I, Rossner S, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A. 2006;103(2):443–448.
   PubMed Web of Science ®Google Scholar
• Chen CH, Zhou W, Liu S, et al. Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease. Int J Neuropsychopharmacol. 2012;15(1):77–90.
   PubMed Web of Science ®Google Scholar
• Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. Bmj. 2003;327(7407):128.
   PubMed Web of Science ®Google Scholar
• Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review. Neuroepidemiology. 2004;23(4):159–169.
   PubMed Web of Science ®Google Scholar
• De Craen AJ, Gussekloo J, Vrijsen B, et al. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol. 2005;161(2):114–120.
   PubMed Web of Science ®Google Scholar
• Szekely CA, Town T, Zandi PP. NSAIDs for the chemoprevention of Alzheimer’s disease. Subcell Biochem. 2007;42:229–248.
   PubMedGoogle Scholar
• Szekely CA, Green RC, Breitner JC, et al. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology. 2008;70(24):2291–2298.
   PubMed Web of Science ®Google Scholar
• Wang J, Tan L, Wang HF, et al. Anti-inflammatory drugs and risk of Alzheimer’s disease: an updated systematic review and meta-analysis. J Alzheimers Dis. 2015;44(2):385–396.
   PubMed Web of Science ®Google Scholar
• Hayden KM, Zandi PP, Khachaturian AS, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology. 2007;69(3):275–282.
   PubMed Web of Science ®Google Scholar
• Waldstein SR, Wendell CR, Seliger SL, et al. Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging. J Am Geriatr Soc. 2010;58(1):38–43.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Skarupski KA, Bienias JL, et al. Anti-inflammatory agents and cognitive decline in a bi-racial population. Neuroepidemiology. 2008;30(1):45–50.
   PubMed Web of Science ®Google Scholar
• Buckley T, Corcoran C, Schwartz S, et al. NSAID use does not affect dementia progression or survival in Alzheimer’s disease. The Cache County dementia progression study. Alzheimers Dement. 2011;7(4):S367.
   Google Scholar
• Wichmann MA, Cruickshanks KJ, Carlsson CM, et al. NSAID use and incident cognitive impairment in a population-based cohort. Alzheimer Dis Assoc Disord. 2016;30(2):105–112.
   PubMed Web of Science ®Google Scholar
• Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology. 1993;43(8):1609–1611.
   PubMed Web of Science ®Google Scholar
• De Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial. PLoS One. 2008;3(1):e1475.
   PubMed Web of Science ®Google Scholar
• Pasqualetti P, Bonomini C, Dal Forno G, et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease. Aging Clin Exp Res. 2009;21(2):102–110.
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21):2819–2826.
   PubMed Web of Science ®Google Scholar
• Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204–1215.
   PubMed Web of Science ®Google Scholar
• Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66–71.
   PubMed Web of Science ®Google Scholar
• Advisory Committee Briefing Document Celecoxib and Valdecoxib Cardiovascular Safety. FDA.gov. [cited 2015 Mar 6]. Available from: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_03_Pfizer-Celebrex-Bextra.pdf
   Google Scholar
• Soininen H, West C, Robbins J, et al. Long-term efficacy and safety of celecoxib in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2007;23(1):8–21.
   PubMed Web of Science ®Google Scholar
• Small GW, Siddarth P, Silverman DH, et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. Am J Geriatr Psychiatry. 2008;16(12):999–1009.
   PubMed Web of Science ®Google Scholar
• Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology. 1999;53(1):197–201.
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer’s disease. Neurology. 2002;58(7):1050–1054.
   PubMed Web of Science ®Google Scholar
• Gomez-Isla T, Blesa R, Boada M, et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord. 2008;22(1):21–29.
   PubMed Web of Science ®Google Scholar
• Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s disease cooperative study. Neurology. 2000;54(3):588–593.
   PubMed Web of Science ®Google Scholar
• Van Gool WA, Weinstein HC, Scheltens P, et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 2001;358(9280):455–460.
   PubMed Web of Science ®Google Scholar
• Alzheimer Disease: Phase 2 Trial Results Reported by Immune Network Ltd. The Free Library [cited 2016 Mar 6]. Available from: http://www.thefreelibrary.com/Alzheimer Disease: Phase 2 Trial Results Reported by Immune Network…-a092852880
   Google Scholar
• Wilcock GK, Black SE, Hendrix SB, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised phase II trial. Lancet Neurol. 2008;7(6):483–493.
   PubMed Web of Science ®Google Scholar
• Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302(23):2557–2564.
   PubMed Web of Science ®Google Scholar
• Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006;63(10):1402–1408.
   PubMed Web of Science ®Google Scholar
• Pomponi MF, Gambassi G, Pomponi M, et al. Why docosahexaenoic acid and aspirin supplementation could be useful in women as a primary prevention therapy against Alzheimer’s disease? Ageing Res Rev. 2011;10(1):124–131.
   PubMed Web of Science ®Google Scholar
• Jaturapatporn D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev. 2012;2:CD006378.
   PubMed Web of Science ®Google Scholar
• Mazereeuw G, Lanctot KL, Chau SA, et al. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging. 2012;33(7):1482, e1417–1429.
   Google Scholar
• Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304(17):1903–1911.
   PubMed Web of Science ®Google Scholar
• Burckhardt M, Herke M, Wustmann T, et al. Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev. 2016;4:CD009002.
   PubMedGoogle Scholar
• ADAPT Research Group, Lyketsos CG, Breitner JC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007; 68(21):1800–1808.
   PubMed Web of Science ®Google Scholar
• ADAPT Research Group, Martin BK, Szekely C, et al. Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008;65(7):896–905.
   PubMedGoogle Scholar
• Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimers Dement. 2011;7(4):402–411.
   PubMed Web of Science ®Google Scholar
• ADAPT-FS Research Group. Follow-up evaluation of cognitive function in the randomized Alzheimer’s disease anti-inflammatory prevention trial and its follow-up study. Alzheimers Dement. 2015;11(2):216–225e211.
   PubMed Web of Science ®Google Scholar
• ADAPT Trial Research Group. Results of a follow-up study to the randomized Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement. 2013;9(6):714–723.
   PubMed Web of Science ®Google Scholar
• Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013;88(11):1213–1221.
   PubMed Web of Science ®Google Scholar
• Kandiah N, Feldman HH. Therapeutic potential of statins in Alzheimer’s disease. J Neurol Sci. 2009;283(1–2):230–234.
   PubMed Web of Science ®Google Scholar
• McGuinness B, Craig D, Bullock R, et al. Statins for the treatment of dementia. Cochrane Database Syst Rev. 2014;7:CD007514.
   Google Scholar
• Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients (SIMaMCI). ClinicaTrials.gov. [ updated 2009 Feb 11; cited 2016 Mar 6]. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT00842920
   Google Scholar
• Campoy S, Sierra S, Suarez B, et al. Semisynthesis of novel monacolin J derivatives: hypocholesterolemic and neuroprotective activities. J Antibiot (Tokyo). 2010;63(8):499–505.
   PubMed Web of Science ®Google Scholar
• Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112(3):440–449.
   PubMed Web of Science ®Google Scholar
• Imbimbo BP. Why did tarenflurbil fail in Alzheimer’s disease? J Alzheimers Dis. 2009;17(4):757–760.
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Giardino L, Sivilia S, et al. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis. 2010;20(1):159–173.
   PubMed Web of Science ®Google Scholar
• Porrini V, Lanzillotta A, Branca C, et al. CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid. Neuroscience. 2015;302:112–120.
   PubMed Web of Science ®Google Scholar
• Ross J, Sharma S, Winston J, et al. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study. Curr Alzheimer Res. 2013;10(7):742–753.
   Web of Science ®Google Scholar
• Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J Neurosci. 2012;32(30):10117–10128.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang LN, Jia JP. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer’s disease and amnestic mild cognitive impairment: a systematic review and meta-analysis. Drugs Aging. 2015;32(1):57–65.
   PubMed Web of Science ®Google Scholar
• Cheng H, Shang Y, Jiang L, et al. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer’s disease and mild-to-moderate Alzheimer’s disease: a meta-analysis. Int J Neurosci. 2016;126(4):299–307.
   PubMed Web of Science ®Google Scholar
• Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer’s Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW). ClinicalTrials.gov. [ updated 2013 Aug 25; cited 2016 Mar 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT01931566
   Google Scholar
• Tong M, Deochand C, Didsbury J, et al. T3D-959: A multi-faceted disease remedial drug candidate for the treatment of Alzheimer’s disease. J Alzheimer’s Dis. 2016;51:123–138.
   PubMed Web of Science ®Google Scholar
• Feasibility Study in Subjects With Mild to Moderate Alzheimer’s Disease. ClinicalTrails.gov. [updated 2015 Jul 28; cited 2016 Mar 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT02560753
   Google Scholar
• Kummer MP, Schwarzenberger R, Sayah-Jeanne S, et al. Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits. Mol Neurobiol. 2015;51(2):661–671.
   PubMed Web of Science ®Google Scholar
• Zhao J, Fu Y, Liu CC, et al. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway. J Biol Chem. 2014;289(16):11282–11292.
   PubMed Web of Science ®Google Scholar
• Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science. 2012;335(6075):1503–1506.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Zhong K, Kinney JW, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease. Alzheimers Res Ther. 2016;8(1):4.
   PubMed Web of Science ®Google Scholar
• Zhao HF, Li N, Wang Q, et al. Resveratrol decreases the insoluble Abeta1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats. Neuroscience. 2015;310:641–649.
   PubMed Web of Science ®Google Scholar
• Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85(16):1383–1391.
   PubMed Web of Science ®Google Scholar
• Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol. 2008;8:27.
   PubMed Web of Science ®Google Scholar
• Butchart J, Brook L, Hopkins V, et al. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;84(21):2161–2168.
   PubMed Web of Science ®Google Scholar
• Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer’s Disease. ClinicalTrials.gov. [updated 2012 Oct 5; cited 2016 Mar 6]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01716637
   Google Scholar
• Alam JJ. Selective Brain-Targeted Antagonism of p38 MAPKalpha reduces hippocampal IL-1beta levels and improves morris water maze performance in aged rats. J Alzheimers Dis. 2015;48(1):219–227.
   PubMed Web of Science ®Google Scholar
• Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer’s Disease (AD) or Mild AD. ClinicalTrials.gov. [updated 2015 Apr 3; cited 2016 Mar 6]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02423200
   Google Scholar
• Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674–678.
   PubMed Web of Science ®Google Scholar
• Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248–255.
   PubMed Web of Science ®Google Scholar
• Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–729.
   PubMed Web of Science ®Google Scholar
• Vom Berg J, Prokop S, Miller KR, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med. 2012;18(12):1812–1819.
   PubMed Web of Science ®Google Scholar
• Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012;79(9):897–905.
   PubMed Web of Science ®Google Scholar
• Town T, Laouar Y, Pittenger C, et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med. 2008;14(6):681–687.
   PubMed Web of Science ®Google Scholar
• Tesseur I, Zou K, Esposito L, et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer’s pathology. J Clin Invest. 2006;116(11):3060–3069.
   PubMed Web of Science ®Google Scholar
• Guillot-Sestier MV, Doty KR, Town T. Innate immunity fights Alzheimer’s disease. Trends Neurosci. 2015;38(11):674–681.
   PubMed Web of Science ®Google Scholar
• Chakrabarty P, Li A, Ceballos-Diaz C, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 2015;85(3):519–533.
   PubMed Web of Science ®Google Scholar
• Baruch K, Deczkowska A, Rosenzweig N, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer’s disease. Nat Med. 2016;22(2):135–137.
   PubMed Web of Science ®Google Scholar
• Baruch K, Rosenzweig N, Kertser A, et al. Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer’s disease pathology. Nat Commun. 2015;6:7967.
   PubMed Web of Science ®Google Scholar
• Dansokho C, Ait Ahmed D, Aid S, et al. Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain. 2016;139(4):1237–1251.
   PubMed Web of Science ®Google Scholar
• Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283–294.
   PubMed Web of Science ®Google Scholar
• Olmos-Alonso A, Schetters ST, Sri S, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Brain. 2016;139(Pt 3):891–907.
   PubMed Web of Science ®Google Scholar
• Spangenberg EE, Lee RJ, Najafi AR, et al. Eliminating microglia in Alzheimer’s mice prevents neuronal loss without modulating amyloid-beta pathology. Brain. 2016;139(4):1265–1281.
   PubMed Web of Science ®Google Scholar
• Lian H, Yang L, Cole A, et al. NFkappaB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer’s disease. Neuron. 2015;85(1):101–115.
   PubMed Web of Science ®Google Scholar
• Lian H, Litvinchuk A, Chiang AC, et al. Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of Alzheimer’s disease. J Neurosci. 2016;36(2):577–589.
   PubMed Web of Science ®Google Scholar
• Mathieu MC, Sawyer N, Greig GM, et al. The C3a receptor antagonist SB 290157 has agonist activity. Immunol Lett. 2005;100(2):139–145.
   PubMed Web of Science ®Google Scholar
• Borroni E, Wyler R, Messer J, et al. Preclinical characterization of RO4602522, a novel, selective and orally active monoamine oxidase type B inhibitor for the treatment of Alzheimer’s disease. Alzheimers Dement. 2013;9(4):P818.
   Google Scholar
• Nave S, Doody RS, Boada Rovira M, et al. Sembragiline in moderate Alzheimer’s disease dementia: results of a Phase 2 trial (Mayflower Road). J Prev Alz Dis. 2015;2(4):276–277.
   Google Scholar
• Leinenga G, Gotz J. Scanning ultrasound removes amyloid-beta and restores memory in an Alzheimer’s disease mouse model. Sci Transl Med. 2015;7(278):278ra233.
   Web of Science ®Google Scholar
• Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160(6):1061–1071.
   PubMed Web of Science ®Google Scholar
• Jiang T, Tan L, Zhu XC, et al. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2014;39(13):2949–2962.
   PubMed Web of Science ®Google Scholar
• Jay TR, Miller CM, Cheng PJ, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J Exp Med. 2015;212(3):287–295.
   PubMed Web of Science ®Google Scholar
• Jiang T, Wan Y, Zhang YD, et al. TREM2 overexpression has no improvement on neuropathology and cognitive impairment in aging APPswe/PS1dE9 mice. Mol Neurobiol. 2016.doi:10.1007/s12035-016-9704-x. [Epub ahead of print]
   Google Scholar
• Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016;17:201–207.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ulland TK, Ulrich JD, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213(5):667–675.
   PubMed Web of Science ®Google Scholar
• Yuan P, Condello C, Keene CD, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90(4):724–739.
   PubMed Web of Science ®Google Scholar
• Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78(4):631–643.
   PubMed Web of Science ®Google Scholar
• Fang F, Lue LF, Yan S, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. Faseb J. 2010;24(4):1043–1055.
   PubMed Web of Science ®Google Scholar
• Galasko D, Bell J, Mancuso JY, et al. Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology. 2014;82(17):1536–1542.
   PubMed Web of Science ®Google Scholar
• Burstein AH, Grimes I, Galasko DR, et al. Effect of TTP488 in patients with mild to moderate Alzheimer’s disease. BMC Neurol. 2014;14:12.
   PubMedGoogle Scholar
• Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer’s Disease (STEADFAST). ClinicalTrials.gov. [updated 2014 Feb 25; cited 2016 Mar 6]. Available from: https://www.clinicaltrials.gov/show/NCT02080364
   Google Scholar
• Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149(11):981–983.
   PubMed Web of Science ®Google Scholar
• Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer’s disease: the epidemiological evidence. CNS Neurol Disord Drug Targets. 2010;9(2):132–139.
   PubMed Web of Science ®Google Scholar
• In T’ Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med. 2001;345(21):1515–1521.
   PubMed Web of Science ®Google Scholar
• Vlad SC, Miller DR, Kowall NW, et al. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008;70(19):1672–1677.
   PubMed Web of Science ®Google Scholar
• Breitner JC, Haneuse SJ, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72(22):1899–1905.
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology. 2008;70(23):2219–2225.
   PubMed Web of Science ®Google Scholar
• Szekely CA, Breitner JC, Fitzpatrick AL, et al. NSAID use and dementia risk in the cardiovascular health study: role of APOE and NSAID type. Neurology. 2008;70(1):17–24.
   PubMed Web of Science ®Google Scholar
• Haag MD, Van Oijen M, De Jong FJ, et al. Amyloid β42-level lowering non-steroidal anti-inflammatory drugs and the risk of Alzheimer’s disease. Alzheimers Dement. 2006;2(Suppl1):S43.
   Google Scholar
• Cornelius C, Fastbom J, Winblad B, et al. Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology. 2004;23(3):135–143.
   PubMed Web of Science ®Google Scholar
• Puhl AC, Milton FA, Cvoro A, et al. Mechanisms of peroxisome proliferator activated receptor gamma regulation by non-steroidal anti-inflammatory drugs. Nucl Recept Signal. 2015;13:e004.
   PubMedGoogle Scholar
• FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. U.S. Food and Drug Administration [cited 2016 Mar 6]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm451800.htm
   Google Scholar
• Wang J, Logovinsky V, Hendrix SB, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry. 2016. doi:10.1136/jnnp-2015-312383. [Epub ahead of print]
   Web of Science ®Google Scholar